Adult Dosing

Hypokalemia, electrolyte replacement [Based on normal daily requirement]

• 40-80 mEq/24 hrs IV at a maximum infusion rate of 1 mEq/kg/hr

• Dilute the injection before use
• Individualize dose and rate of infusion based on needs of the patient
• May be administered as intraosseous infusion when IV access in not readily available

Pediatric Dosing

Hypokalemia, electrolyte replacement [Based on normal daily requirement]

• Newborn
• 2-6 mEq/kg/24 hrs IV at a maximum infusion rate of 1 mEq/kg/hr

• Children
• 2-3 mEq/kg/24 hrs IV at a maximum infusion rate of 1 mEq/kg/hr

• Dilute the injection before use
• Individualize dose and rate of infusion based on needs of the patient
• May be administered as intraosseous infusion when IV access in not readily available

[Outline]

• Adult Dosing
• Pediatric Dosing

• Source of potassium for addition to large volume IV fluids for prevention or correction of hypokalemia in patients with restricted or no salt intake
• Additive in preparation of IV formulas when needs of the patient cannot be met by standard electrolyte/nutrient solutions

• Hypersensitivity to any of the ingredients of the product
• Severe renal insufficiency
• Adrenal insufficiency
• Conditions exhibiting high potassium levels

• N/A

Renal Dose Adjustment

• Mild-moderate renal impairment: Dose adjustments not defined, caution advised
• Severe renal impairment: Contraindicated

Hepatic Dose Adjustment

• Hepatic impairment: Dose adjustments not defined, caution advised

• Dilute the injection before use
• Solutions containing potassium must be infused slowly to avoid risk of potassium intoxication. Monitor ECG continuously during therapy
• Serum potassium levels may not accurately indicate potassium levels in tissue
• Use cautiously in patients with hyperkalemia, renal failure and conditions involving potassium retention
• Acetate solutions must be used with caution in patients with metabolic or respiratory alkalosis and severe hepatic insufficiency
• High levels of potassium in plasma may result in fatal cardiac depression, arrhythmias or arrest. Use with caution in patients with cardiac disease, especially digitalized patients

Cautions: Use cautiously in

• Severe hepatic insufficiency
• Mild-moderate renal insufficiency
• Potassium retention
• Hyperkalemia
• Metabolic/respiratory alkalosis
• Cardiac disease
• Premature neonates

Pregnancy Category:C

Breastfeeding: Safety unknown.

• CV: Hypotension, cardiac arrhythmias, heart block, ECG abnormalities (disappearance of P waves, spreading and slurring of QRS complex, development of biphasic curve), cardiac arrest
• CNS: Mental confusion
• NEURO: Paresthesias of extremities, flaccid paralysis
• MISC: Potassium intoxication, listlessness, weakness and heaviness of legs

• Electrolyte; potassium is the principal intracellular cation, plays an important role in maintenance of fluid and electrolyte balance
• Metabolism: Unknown
• Excreted in urine
• Half-life: Unknown

US Trade Name(s)

• Only generic available

US Availability

potassium acetate (generic)

• INJ: 2 mEq/mL (50 mL vial)

Canadian Trade Name(s)

• Only generic available

Canadian Availability

potassium acetate (generic)

• INJ: 392 mg/mL

UK Trade Name(s)

• N/A

UK Availability

• N/A

Australian Trade Name(s)

• DBL Potassium Acetate Concentrated Injection

Australian Availability

DBL Potassium Acetate Concentrated Injection

• INJ: 2.45 g/5 mL (5 mL ampoule)

[Outline]

Nutrition/Electrolytes

Minerals & Electrolytes